Free Trial
NASDAQ:LYEL

Lyell Immunopharma Q3 2023 Earnings Report

Lyell Immunopharma logo
$0.41 +0.00 (+0.24%)
As of 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lyell Immunopharma EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Lyell Immunopharma Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$2.50 million
Beat/Miss
Missed by -$2.47 million
YoY Revenue Growth
N/A

Lyell Immunopharma Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Lyell Immunopharma's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Lyell Immunopharma Earnings Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Lyell Immunopharma announces FDA granted RMAT designation to LYL314
See More Lyell Immunopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lyell Immunopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lyell Immunopharma and other key companies, straight to your email.

About Lyell Immunopharma

Lyell Immunopharma (NASDAQ:LYEL), a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

View Lyell Immunopharma Profile

More Earnings Resources from MarketBeat